2023
Discovery of decreased ferroptosis in male colorectal cancer patients with KRAS mutations
Yan H, Talty R, Jain A, Cai Y, Zheng J, Shen X, Muca E, Paty P, Bosenberg M, Khan S, Johnson C. Discovery of decreased ferroptosis in male colorectal cancer patients with KRAS mutations. Redox Biology 2023, 62: 102699. PMID: 37086630, PMCID: PMC10172914, DOI: 10.1016/j.redox.2023.102699.Peer-Reviewed Original ResearchMeSH KeywordsCell Line, TumorColorectal NeoplasmsFemaleFerroptosisHumansMaleMetabolomicsPrognosisProto-Oncogene Proteins p21(ras)Sex FactorsConceptsKRAS mutant tumorsMale CRC patientsCRC patientsMale patientsKRAS mutationsMutant tumorsOverall survivalMale colorectal cancer patientsKRAS wild-type tumorsAberrant tumor metabolismColorectal cancer patientsCRC patient cohortsColorectal cancer casesFerroptosis-related genesWild-type tumorsNovel potential avenuesNormal colon tissuesPoor OSKRAS statusAdverse outcomesCRC cellsPatient cohortCancer patientsType tumorsCancer cases
2021
5‐Fluorouracil efficacy requires anti‐tumor immunity triggered by cancer‐cell‐intrinsic STING
Tian J, Zhang D, Kurbatov V, Wang Q, Wang Y, Fang D, Wu L, Bosenberg M, Muzumdar MD, Khan S, Lu Q, Yan Q, Lu J. 5‐Fluorouracil efficacy requires anti‐tumor immunity triggered by cancer‐cell‐intrinsic STING. The EMBO Journal 2021, 40: embj2020106065. PMID: 33615517, PMCID: PMC8013832, DOI: 10.15252/embj.2020106065.Peer-Reviewed Original ResearchConceptsAnti-tumor immunityTumor burdenSubsequent type I interferon productionHigh STING expressionIntratumoral T cellsT-cell depletionType I interferon productionI interferon productionLoss of STINGImmunocompetent hostsColorectal specimensT cellsSTING expressionBetter survivalHigh doseTherapeutic effectivenessHuman colorectal specimensMelanoma tumorsInterferon productionChemotherapeutic drugsMurine colonImmunityEfficacyStingsColon
2015
Oncogenic CXCL10 signalling drives metastasis development and poor clinical outcome
Wightman SC, Uppal A, Pitroda SP, Ganai S, Burnette B, Stack M, Oshima G, Khan S, Huang X, Posner MC, Weichselbaum RR, Khodarev NN. Oncogenic CXCL10 signalling drives metastasis development and poor clinical outcome. British Journal Of Cancer 2015, 113: 327-335. PMID: 26042934, PMCID: PMC4506383, DOI: 10.1038/bjc.2015.193.Peer-Reviewed Original ResearchConceptsClinical outcomesMetastatic potentialPoor clinical outcomePoor overall survivalMetastatic disease progressionExpression of CXCL10Renal cell carcinomaFunction of CXCL10Increased metastatic potentialIndividual tumor clonesTumor cell growthClinical data setsMetastatic diseaseOverall survivalMetastatic recurrenceCell carcinomaDifferent metastatic abilityCXCR3 pathwayCytokine profilingDisease progressionOncogenic axisCXCR3Metastasis developmentAvailable clinical data setsCXCL10
2012
Tumor Endothelial Inflammation Predicts Clinical Outcome in Diverse Human Cancers
Pitroda SP, Zhou T, Sweis RF, Filippo M, Labay E, Beckett MA, Mauceri HJ, Liang H, Darga TE, Perakis S, Khan SA, Sutton HG, Zhang W, Khodarev NN, Garcia JG, Weichselbaum RR. Tumor Endothelial Inflammation Predicts Clinical Outcome in Diverse Human Cancers. PLOS ONE 2012, 7: e46104. PMID: 23056240, PMCID: PMC3464251, DOI: 10.1371/journal.pone.0046104.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAnimalsBreast NeoplasmsCell Line, TumorCells, CulturedColonic NeoplasmsEndothelial CellsEndothelium, VascularFemaleGene Expression ProfilingGliomaHuman Umbilical Vein Endothelial CellsHumansInflammationKaplan-Meier EstimateLung NeoplasmsMaleMiceMiddle AgedMultivariate AnalysisNeoplasmsNeovascularization, PathologicOligonucleotide Array Sequence AnalysisTumor Necrosis Factor-alphaConceptsEndothelial inflammationEndothelial cellsOverall survivalHuman cancersDiverse human cancersExperimental modelTumor-associated endothelial cellsStromal inflammatory responsePathological prognostic factorsEndothelial-derived factorsPro-inflammatory cytokinesInflammatory gene expressionPathologic tissue specimensUntreated endothelial cellsVascular endothelial cellsMultiple human cancersInflammatory signatureHuman endothelial cellsPrognostic factorsClinical outcomesChronic inflammationInflammatory pathwaysLung cancerTumor necrosisInflammatory response
2011
MicroRNA Expression Characterizes Oligometastasis(es)
Lussier YA, Xing HR, Salama JK, Khodarev NN, Huang Y, Zhang Q, Khan SA, Yang X, Hasselle MD, Darga TE, Malik R, Fan H, Perakis S, Filippo M, Corbin K, Lee Y, Posner MC, Chmura SJ, Hellman S, Weichselbaum RR. MicroRNA Expression Characterizes Oligometastasis(es). PLOS ONE 2011, 6: e28650. PMID: 22174856, PMCID: PMC3236765, DOI: 10.1371/journal.pone.0028650.Peer-Reviewed Original ResearchConceptsOligometastatic patientsMetastasis-directed treatmentMetastasis-directed therapyHigh-dose radiotherapyPredictors of progressionMicroRNA-200 (miR-200) familyPolymetastatic progressionMetastatic diseasePatient selectionLocal treatmentCancer stagingMetastatic outcomeXenograft modelMicroRNA classifierPatientsPolymetastasesTumor samplesOligometastasesCell linesTreatmentProgressionBiological basisRadiotherapyExpressionTherapy
2008
c-Met gene amplification is associated with advanced stage colorectal cancer and liver metastases
Zeng ZS, Weiser MR, Kuntz E, Chen CT, Khan SA, Forslund A, Nash GM, Gimbel M, Yamaguchi Y, Culliford AT, D’Alessio M, Barany F, Paty PB. c-Met gene amplification is associated with advanced stage colorectal cancer and liver metastases. Cancer Letters 2008, 265: 258-269. PMID: 18395971, PMCID: PMC4367187, DOI: 10.1016/j.canlet.2008.02.049.Peer-Reviewed Original ResearchConceptsC-MET gene amplificationC-Met gene copy numberLiver metastasesPrimary colorectal cancerColorectal cancerGene amplificationC-MetAdvanced stage colorectal cancerAdvanced colorectal cancerStage colorectal cancerNormal colonic mucosaLiver resectionTyrosine kinaseGene copy numberDistant metastasisPrimary cancerLung cancerColonic mucosaGastric cancerNormal mucosaMetastasisNormal liverTumor growthMetastatic progressionLiver tissue